Vicriviroc is a CCR5 antagonist, a class of antiretroviral drugs investigated for the treatment of HIV-1 infection by blocking the entry of the virus into CD4+ T-cells. This category features high-quality… Read more
Vicriviroc is a CCR5 antagonist, a class of antiretroviral drugs investigated for the treatment of HIV-1 infection by blocking the entry of the virus into CD4+ T-cells. This category features high-quality reference standards essential for pharmaceutical analysis, including Vicriviroc API and its malate salt. In addition to the parent drug, researchers can access related compounds, such as stable isotope labelled analogues like Vicriviroc-13C-d3, which serve as internal standards in mass spectrometry. These compounds are critical for conducting robust impurity profiling, developing sensitive analytical methods, and maintaining stringent quality control throughout preclinical and clinical drug development pipelines. Laboratories rely on these well-characterized materials to ensure accurate quantification of active ingredients and the identification of potential degradation products or synthesis-related impurities, thereby supporting regulatory compliance and the integrity of HIV-1 research programs.